Evelo Biosciences, Inc. announced that David Epstein has been appointed chairman of its Board of Directors. Mr. Epstein has been a director of Evelo since March 2017. Noubar Afeyan, Ph.D., a co-founder of Evelo and chief executive officer of Flagship Pioneering, is stepping down after serving as chairman of the Board since Evelo’s founding in 2014. Mr. Epstein currently serves as chairman of the Board of Directors of Rubius Therapeutics, chairman of the Board of Directors of Axcella Health, and as a director at International Flavors and Fragrances. From January 2010 to July 2016, Mr. Epstein served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG. Mr. Epstein received his M.B.A. from Columbia University Graduate School of Business. In addition, in order that each class of the Board following Dr. Afeyan's resignation consists, as nearly as may be possible, of one-third of the total number of directors then constituting the entire Board, Mr. Epstein agreed to resign as a Class II director effective immediately prior to his appointment as a Class III director, which appointment was effective on September 14, 2019. As a Class III director, Mr. Epstein is to serve until the Company's annual meeting of stockholders to be held in 2021 and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal.